Understanding how transcription switches from elongation to termination in human cells to help cancer outcomes
Official title: Unraveling the Molecular Mechanisms Governing the Elongation-to-Termination Transition of RNA Polymerase II-Dependent Transcription
Funded at Albert Einstein College of Medicine · NIH-11432028 · Data updated 2026-11-12
This grant studies how RNA polymerase II finishes copying genes, which could reveal new ways to improve cancer treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project start | August 1, 2026 |
| Project end | July 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $1,764,002 |
| NIH project number | 1R01GM166716-01 |
| Project ID | NIH-11432028 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with cancers where transcriptional misregulation is known to influence prognosis may benefit from future translation of these findings.
✕Less likely to help
Healthy individuals or patients with cancers not driven by transcriptional misregulation may not directly benefit from this research.
What this research studies
Researchers will dissect the molecular steps that move RNA polymerase II from elongation to termination in human cells, focusing on the roles of kinases and transcription factors. The work combines molecular biology, biochemistry, and cell-based assays to map how gene expression is precisely controlled. By linking misregulation to cancer prognosis, the project aims to identify potential targets for novel therapies and better biomarkers. This approach directly ties fundamental transcription biology to potential improvements in cancer care.
Why it matters
Potential benefit: If successful, it could lead to new targets or strategies to slow cancer progression and improve treatment responses by modulating transcriptional termination.
How similar studies have gone: Previous studies have shown that altering transcriptional control can impact cancer-related gene expression and treatment responses, supporting this approach as promising but still expanding knowledge.
Where this research is happening
-
Albert Einstein College of Medicine
Bronx, United States Active
Researchers
- Principal investigator: Parua, Pabitra Kumar — Albert Einstein College of Medicine
- Study coordinator: Parua, Pabitra Kumar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.